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The cyclic AMP-speciﬁc phosphodiesterase PDE8 has been shown to play a pivotal role in important
processes such as steroidogenesis, T cell adhesion, regulation of heart beat and chemotaxis. How-
ever, no information exists on how the activity of this enzyme is regulated. We show that under ele-
vated cAMP conditions, PKA acts to phosphorylate PDE8A on serine 359 and this action serves to
enhance the activity of the enzyme. This is the ﬁrst indication that PDE8 activity can be modulated
by a kinase, and we propose that this mechanism forms a feedback loop that results in the restora-
tion of basal cAMP levels.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction been established, but the function of more recently discoveredCyclic-adenosine monophosphate (cAMP) is a ubiquitous sec-
ond messenger that underpins a wide variety of important cellular
functions. Although produced in response to stimulation of many
different types of G-protein coupled receptors, cAMP signals can
maintain speciﬁcity of receptor action by forming gradients inside
cells that are shaped in space and time by pools of receptor associ-
ated phosphodiesterases, the only known superfamily of enzymes
that can hydrolyze cAMP [1]. Dynamic cAMP gradients are then
‘sampled’ directly by localized cAMP effector proteins such as pro-
tein kinase A (PKA) and exchange protein directly activated by
cAMP (EPAC) that act to trigger receptor speciﬁc functions. Work
utilizing genetically encoded cAMP reporters has demonstrated
that compartmentalisation and regulation of phosphodiesterases
(PDEs) is crucial to underpin signal-speciﬁc responses [2]. PDEs
are divided into 11 families and are characterized by their ability
to hydrolyze either cAMP, cyclic guanine monophosphate (cGMP)
or both cyclic nucleotides and by their modular structure [3]. Phys-
iological roles for some of the better studied PDE families havechemical Societies. Published by E
otein kinase A; cAMP, cyclic-
_dependent protein kinase;
ated by cAMP; cGMP, cyclic
ilding, Gardiner Lab, Univer-
: +44 0141 330 4365.
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uthors.PDEs has been largely unexplored due to a lack of suitable selective
pharmacological inhibitors.
Recently, there has been a surge in interest in the PDE8 family
of PDEs due to their implication in steroidogenesis [4,5], T cell
adhesion [6], lymphocyte chemotaxis [7] and excitation–contrac-
tion coupling [8]. Although important in all these cellular pro-
cesses, nothing is known about how the activity of PDE8 is
regulated. Sequence analysis of the full-length open reading frame
of PDE8A has uncovered an N-terminal signaling motif known as a
known as the Per, ARNT and Sim (PAS) domain [9]. PAS domains
are known to direct protein–protein interactions and are likely to
play a role in PDE8 regulation. Other interesting motifs that have
been deduced from PDE8 sequences are a receiver (REC) domain,
consensus sites for N-glycosylation, N-myristoylation, amidation
and putative kinase substrate sites for PKC, casein kinase [10]
and PKA [11]. It should be stressed that all of these sites are hypo-
thetical and post-translation modiﬁcation of PDE8 has never, be-
fore now, been observed. Using novel peptide array technology
and phospho-site speciﬁc antibodies, we demonstrate that during
times of elevated cAMP, PKA phosphorylates PDE8A on serine
359 and this event triggers the activation of the enzyme.
2. Materials and methods
2.1. Reagents
Forskolin, dipyridamole and 3-isobutyl-1-methylxanthine
(IBMX) were dissolved in dimethyl sulfoxide (DMSO) and addedlsevier B.V. All rights reserved.
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by Sigma (UK). The following antibodies were used in this study,
anti-FLAG (Cell Signalling technology, USA: Cat. No. 2368), anti-
PKA phospho-substrate (Cell Signalling technology, USA: Cat. No.
9621) anti-CREB (Cell Signalling technology, USA: Cat. No. 9197)
anti-phospho CREB (Cell Signalling technology, USA: Cat. No.
9198). In addition, anti-phospho PDE8A1 serine 359 antibody
was custom made by AMS Biotechnology (Europe) in rabbits
against a phosphorylated peptide corresponding to residues
354DRRKGPSLDVKA364. Total PDE8A antibody was purchased from
Scottish Biomedical, UK.
2.2. Immunocytochemistry
Endogenous phospho-PDE8A was visualized in HeLa cells using
immunocytochemistry techniques. Brieﬂy, media on cells was re-
placed with serum free DMEM containing 150 nM Mitotracker
Red CMXRos, a mitochondrion-selective probe (Molecular Probes,
Invitrogen), and induced with the addition of forskolin (100 lM)
if required. Cells were washed with PBS, ﬁxed with 4% (w/v) para-
formaldehyde, washed a further two times in tris-buffered saline
(TBS; 150 mM NaCl, 20 mM Tris, pH 7.4) and permeabilized with
three successive incubations with 0.1% Triton-X 100 in TBS. Cells
were blocked in blocking buffer (10% of the appropriate serum,
2% BSA in TBS) for 2 h at room temperature. Incubation with the
phospho-serine 359 PDE8A antibody at a dilution of 1:400 in a
1:1 solution of blocking buffer:TBS took place at room temperature
for 2 h. Where blocking peptide was used, the peptide was incu-
bated with diluted primary antibody for 1 h at room temperature
before addition to the cells. Cells were washed with blocking solu-
tion three times prior to incubation with a 1:10000 dilution of
Alexa 488-conjugated F(‘ab)2 fragment IgG (Molecular Probes,
Invitrogen). Washes with TBS were performed prior to mounting
coverslips onto microscope slides with Immunomount ProLong
Gold reagent with DAPI (Molecular Probes, Invitrogen) and visual-
ized using a Zeiss Pascal laser-scanning confocal microscope with a
Zeiss Plan-Apo 63  1.4 NA oil immersion objective.
2.3. Peptide array
Peptide libraries were produced by automatic SPOT synthesis
and synthesized on continuous cellulose membrane supports on
Whatman 50 cellulose membranes using Fmoc-chemistry with
the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments
AG, Köln, Germany) as previously described by us [12]. PKA phos-
phorylation of an immobilized library of PDE8 peptides was under-
taken using puriﬁed PKA catalytic subunit (Promega). Recombinant
kinase was diluted in phosphorylation buffer (100 mM Tris–HCl pH
7.5, 0.2 mM ATP, 10 mMMgCl2, 30 mM b-mercaptoethanol, 20% (v/
v) glycerol and 10 mM Calyculin A) and incubated with arrays at
30 C for 30 min with shaking. Control experiments without addi-
tion of recombinant kinase were also done.
2.4. Phosphodiesterase assay and cellular transfection of PDE8A1
Phosphodiesterase activity was measured using a radioactive
cAMP hydrolysis assay that has been described previously [13–
15]. [8-3H] adenosine cyclic-30,50-mono-phosphate was sourced
from Amersham Biosciences (Little Chalfont, UK) and cyclic-30,50-
mono-phosphate from Sigma. The substrate concentration used
for PDE assays was 150 nM, and the speciﬁc PDE activity obtained
was between 100–200 pmol cAMP/mg/ml. PDE activities were
then normalized for expression of PDE8A1, and data was normal-
ized to DMSO-treated PDE8A1 wild type activity. FLAG-tagged
wild-type, Ser359Ala and Ser359Asp PDE8A1 constructs were
transfected into COS7 cells (PDE assay) using Polyfect reagent(Qiagen). HEK293/HeLa cells were transfected, with the appropri-
ate Flag-tagged PDE8A constructs (wildtype/dominant negative/
S359A/S359D) for 48 h using Polyfect. For particular experiments,
cells were pre-treated with KT5720 (4 lM) or H-89 (10 lM) for
20 min prior to treatment with forskolin (100 lM) for speciﬁc
timepoints. Dipyridamole (100 lM) was added to the cell media
after the transfection period. Cells were harvested in lysis buffer
(25 mM Hepes/2.5 mM EDTA/50 mM NaC1/50 mM NaF/30 mM so-
dium pyrophosphate/10% glycerol/1% Triton X-100, pH 7.5, with
addition of protease inhibitors). To conﬁrm efﬁcient phosphoryla-
tion of wild-type PDE8A1 after forskolin treatment, samples were
also blotted using anti-phospho Ser359 antibody.
2.5. In vitro PKA phosphorylation of PDE8
Puriﬁed MBP-PDE8A1 (50 lg) was incubated with increasing
amounts of the active catalytic unit of PKA (0.5, 6.2, 12.5 and
25 lg) in PKA phosphorylation buffer (20 mM Tris–HCl [pH7.5];
100 mM NaCl; 5 mM MgCl2; 1 mM DTT 0.2 mg/ml BSA) plus ATP
(100 mM) for 1 h at 30 C with agitation. The samples were run
on an SDS–PAGE gel and immunoblotted with a PKA phospho-sub-
strate antibody.
2.6. Cloning and puriﬁcation of MBP-PDE8A1
Human ﬂag-tagged PDE8A1 in the pCMV-2 plasmid was a gift
from Professor Kenji Omori (Japan). The PDE8A1 open reading
frame was cloned into a pMAL-c2x vector (NEB) using the follow-
ing primers to incorporate the SalI and XbaI recognition sites. For-
ward primer: AATCTAGAATGGGCTGTGCCCCGA. reverse primer:
AAGTCGACCTATTCAGGAGGTGGTC. BL21 competent cells (Invitro-
gen) were transformed and MBP fusion puriﬁed as described previ-
ously by us [13].
2.7. Site directed mutagenesis of PDE8A1
Site-directed mutagenesis was performed using the Quick-
change kit (Stratagene) according to manufacturer’s instructions.
The following primers were used to create the required mutations.
PDE8A1 dominant negative D726A mutant, forward primer:
GCTGATTAAATGTGCTGCTGTGTCCAATCCCTGCC, reverse primer:
GGCAGGGATTGGACACAGCAGCACATTTAATCAGC, PDE8A1 S359A
mutant, forward primer: AAGACAGGAGAAAAGGCGCACTAGACGT-
CAAAGCT, reverse primer: AGCTTTGACGTCTAGTGCGCCTTTTCTCC-
TGTCTT, PDE8A1 S359D mutant, forward primer: CATAAAGACAG-
GAGAAAAGGCGATCTAGACGTCAAAGCTGTTGCC, reverse primer:
GGCAACAGCTTTGACGTCTAGATCGCCTTTTCTCCTGTCTTTATG. All
mutations were veriﬁed by sequencing.
3. Results
3.1. Delineation of a PKA site on PDE8A using peptide array technology
As it has been hypothesized that PDE8A may be phosphorylated
by PKA, we incubated increasing amounts of puriﬁed MBP-PDE8A
with a PKA assay mix containing active puriﬁed PKA catalytic unit.
We then blotted the resulting proteins with an antibody that rec-
ognizes phospho-PKA substrates containing the sequence R-x-x-
pS (where x is any amino-acid and pS is phospho-serine). Equiva-
lent amounts of puriﬁed MBP-PDE8A were loaded (Fig. 1A lower
panel), however, only samples containing active PKA catalytic unit
were recognized by the phospho-PKA substrate antibody suggest-
ing that PDE8A could indeed be directly phosphorylated by PKA.
Peptide array represents a novel method to look at post-trans-
lational modiﬁcation of proteins. Recently we have used this meth-
od to delineate SUMOylation [13] and ubiquitination sites [16] on
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3-kinase (PI3K) [17] and DNA_dependent protein kinase (DNAPK)
[18]. As sequence analysis of PDE8A has three predicted PKA sites
[11] (Fig. 1B), we decided to use peptide array to see if any or all of
these sites could be phosphorylated by the kinase. Peptide arrays
of overlapping 25-mer peptides, sequentially shifted by 5 amino
acids and spanning the entire PDE8A sequence, were incubated
with a PKA assay mix before detection of phosphorylation using
a phosphorylation dependent antibody. Dark spots represent posi-
tive areas of phosphorylation whereas clear spots are negative for
the modiﬁcation by PKA (Fig. 1C). Doing this we observed that
whilst no signal was observed for control PDE8A arrays (-PKA) or
peptides containing putative PKA sites spanning residues
376RRHSS380 and 454RRLSG458 (data not shown), positive signals
were obtained for spots containing 356RKGSL360 (Fig. 1C). To ensure
that the phosphate group was being added to serine 359 and that
successful phosphorylation depended on the PKA consensus se-
quence, an identical experiment was carried out on immobilized
peptides in which single or double alanine substitutions of the ori-
ginal peptide (351K-375R) were made (Fig. 1C, lower panel). Alanine
substitution of either 359S or the basic amino acids at 356R, 357K in
the PKA consensus motif both severely attenuated phosphoryla-
tion. These data suggests that only one of the three possible PKA
sites actually act as a substrate for PKA and that phosphorylation
depends on the consensus 356RKXS359. As the sequences of PDE8A
and PDE8B are relatively conserved around the region against
which the phospho-PDE8A antibody was raised, we were keen to
demonstrate the speciﬁcity of our anti-serum in detecting solelyFig. 1. PKA phosphorylates PDE8A1 on serine 359. (A) Puriﬁed MBP-PDE8A1 was phosph
substrate antibody. (B) A schematic diagram indicating the three putative PKA sites on PD
to show that serine 359 is the PKA site on PDE8A1. (D) Peptide arrays of the cognate PD
serine and phospho-mimic serine to aspartate or glutamic acid substitution were probephospho-PDE8A. To this end, we constructed peptide arrays of
the cognate PDE8A and PDE8B sequences either containing the
phospho-serine, unphosphorylated serine and phospho-mimic ser-
ine to aspartate or glutamic acid substitution (Fig 1D). We probed
the arrays with the phospho-PDE8A antibody and cross reactivity
was seen only with the PDE8A sequence when a phospho-serine
was present. These new data suggests the subtle differences in se-
quence between PDE8A and PDE8B in the vicinity of the PKA site is
enough to ensure speciﬁc recognition of phosphorylated PDE8A by
our phospho-PDE8A antibody.
3.2. Characterization of a phospho serine 359 antibody
To investigate whether PDE8A is a PKA substrate in a cellular
context, we commissioned a phospho-site speciﬁc antibody to ser-
ine 359. The antibody recognized a band corresponding to FLAG-
PDE8A only after cells were stimulated with the adenylyl cyclase
activator forskolin (FSK) (Fig 2A). This band was signiﬁcantly
(P < 0.05, Student’s T test, n = 3) reduced following pre-treatment
of the cells with the PKA inhibitors H89 and KT5720 (Fig 2A).
The phosphorylation of another PKA substrate, CREB, was also
equally diminished following KT5720 pre-treatment (Fig. 2G).
Additionally, the antibody did not recognize PDE8A following for-
skolin treatment if serine 359 was mutated to either alanine or
aspartic acid (Fig 2B), verifying the speciﬁcity of the antibody for
phosphorylation of a single site. The antibody could also be used
to detect phosphorylation of both exogenous and endogenous
PDE8A, as samples isolated from untransfected HEK293 cells gaveorylated in vitro using the catalytic subunit of PKA and blotted with a phospho-PKA
E8A. (C) Peptide array technology combined with in vitro phosphorylation was used
E8A and PDE8B sequences either containing the phospho-serine, unphosphorylated
d with the phospho-PDE8A antibody.
Fig. 2. PDE8A1 is phosphorylated by PKA in cells. (A) Using a phospho-serine 359 speciﬁc antibody, the phosphorylation of PDE8A1 was shown to be PKA dependent as pre-
treatment with PKA inhibitors H89 (10 lM) and KT5720 (4 lM) reduced phosphorylation levels. (B) The phosphorylation of transfected and endogenous PDE8A1 was
triggered by the adenylyl cyclase activator, forskolin (100 lM) for 5 min. (C) Mutation of serine 359 completely blocked PDE8A1 phosphorylation by PKA. (D) The
phosphorylation of endogenous PDE8A1 was observed in cardiac myocytes following treatment with isoprenaline (10 lM). (E) The PDE8 inhibitor, dipyridimole (50 lM)
induced PDE8A1 phosphorylation. (F) A dominant negative, catalytically dead form of PDE8A1 was more readily phosphorylated by PKA following forskolin (100 lM)
treatment. (G) The induction of phospho-CREB following forskolin treatment (100 lM for 5 min) is partially attenuated by KT5720. (H) Increases in PDE8A1 phosphorylation
triggered by dipyridimole (50 lM for 20 min) were attenuated by KT5720.
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forskolin (Fig. 2C, lower panel). The signal was obviously reduced
compared with protein from cells transfected with FLAG-PDE8A
(Fig. 2C, upper panel), but in both cases, temporal increases in
PDE8A phosphorylation were observed. Increases in PKA phos-
phorylation of PDE8 could also be detected in cellular lysates iso-
lated from neonatal cardiac myocytes following a timecourse of
isoprenaline stimulation (Fig. 2D). Finally, inhibition of PDE8 activ-
ity using either pharmacological means via dipyridimole (Fig. 2E)
or a catalytically inactive version of PDE8A (Fig. 2F) resulted in
an increase in PDE8A phosphorylation compared with wild type
PDE8A. Inhibition of PKA by KT570 diminished the increase in
PDE8A phosphorylation induced by dipyridimole (Fig. 2H). Such in-
creases in phosphorylation could be seen under basal cAMP con-
centrations (Fig. 2E and F, compare zero time point samples)
suggesting that the intrinsic activity of the enzyme protects itself
from ‘‘inappropriate’’ PKA phosphorylation when cAMP is low.
Conversely, conditions of high cAMP, promoted PKA phosphoyla-
tion of wild type PDE8A that was more robust and reached its peak
earlier in the catalytically dead form (Fig. 2F) when compared with
wild type. Such ﬁndings suggest that the antibody we have devel-
oped is a useful tool to detect PKA dependent phosphorylation of a
single site on PDE8A at serine 359 and that under basal conditions,
this site is protected by the enzyme’s catalytic activity, which acts
to dampen localized PKA activity.3.3. Visualisation of PDE8A phosphorylation in HELA cells
As the phospho-serine 359 antibody had been effective in
detecting endogenous levels of PDE8 phosphorylation using wes-
tern blotting (Fig. 2), we decided to determine whether we could
visualize this in cells using immuno-cytochemical methods. Little
endogenous phospho-PDE8A could be detected under basal cAMP
conditions (Fig. 3), however a strong signal was observed following
3 min of forskolin treatment and this was still evident after 10 min.
Phosphorylation of PDE8 appeared to occur throughout the cell,
being particularly evident in the cytoplasm and nucleus but with
no obvious plasma-membrane staining. Very little signal for phos-
pho-PDE8 was observed in control experiments where the anti-
body had been pre-incubated with the peptide against which it
was raised. This further conﬁrmed the speciﬁcity of the antibody.
3.4. PKA phosphorylation activates PDE8A
Phosphorylation and activation of phosphodiesterase enzymes
by PKA provides a feedback loop where increased cAMP stimulates
phosphodiesterase activity to reduce levels of the second messen-
ger back to basal levels following activation of a Gs-coupled recep-
tor. This type of regulation has been shown for PDE4 and PDE3 [19]
and we were interested to determine whether PDE8A activity was
similarly affected. Lysates isolated from HEK293 cells that had
Fig. 3. Visualisation of PDE8A phosphorylation in HELA cells. (A) The PKA phosphorylation of PDE8A was induced by forskolin. (B) The phospho-peptide against which the
phospho-serine 359 antibody was raised blocks the signal triggered by forskolin.
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containing the substitutions S359A/S359D were tested for PDE
activity and PKA phosphorylation of PDE8A (Fig. 4). Wild type
PDE8A activity was signiﬁcantly stimulated following forskolin
treatment (ANOVA, P = 0.003) whereas the S359A mutant was
not suggesting that PKA phosphorylation at that site resulted in
the activation of the enzyme. Interestingly, substitution of serine
359 with a negatively charged aspartic acid residue (to mimic
phosphorylation) produced an activation that was similar in
magnitude and signiﬁcance to FSK treatment (ANOVA, P = 0.004).
There was also a signiﬁcant difference between forskolin-
stimulated WT PDE8A activity versus DMSO-stimulated S359A
PDE8A activity (ANOVA, P = 0.04) and also a signiﬁcant difference
between forskolin-stimulated WT PDE8A activity and forskolin-
stimulated S359A PDE8A activity (ANOVA, P = 0.03). These data
suggest that PKA phosphorylation of PDE8A on serine 359 activates
the enzyme.4. Discussion
As cAMP is a ubiquitous second messenger that can be synthe-
sized to evoke cellular reaction to the activation of a plethora of
membrane associated receptors, speciﬁcity of receptor action must
be underpinned by discrete compartmentalisation of signaling
intermediates within the cAMP signaling system [20]. One method
by which cells rapidly control cAMP dynamics is by regulation of
the activity and localization of cAMP-speciﬁc phosphodiesterases
via post-translational modiﬁcation. Phosphorylation of enzymes
from the phosphodiesterase 4 family by speciﬁc kinases can acti-
vate [21], inhibit [22] or modify the outcome of a pre-existing
phosphorylation by a different kinase [22]. PDE4 enzymes can also
be modiﬁed by SUMO to enhance activation following PKA phos-
phorylation [13] and by ubiquitin to promote a complex with the
scaffolding protein barrestin [16] that leads to a more efﬁcient
desensitization of the b-adrenergic receptor. It has also been
Fig. 4. PDE8 activity is signiﬁcantly enhanced following PKA phosphorylation. (A) Forskolin (100 lM for 10 min) treatment signiﬁcantly enhanced PDE8A activity and this
was recapitulated with the phospho-mimic mutant S359D. ⁄ denotes signiﬁcant changes as calculated using ANOVA analysis. See Section 3. (B) Samples used in (A) were
monitored for PKA phosphorylation.
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PDE3 isoforms [24]. So although it is known that cells can upregu-
late PDE protein expression to combat chronic increases in cAMP
[25,26], almost instant feedback or feed forward regulation of
cAMP can be achieved via modiﬁcation of existing levels of PDE.
Interest in the PDE8 family increases as new and important
roles for these enzymes are found. It is clear from recent work that
PDE8 activity is fundamental to processes such as steroidogenesis
[5] and excitation–contraction coupling [8], however little infor-
mation exists on the molecular mechanisms that regulate ﬁne con-
trol of PDE8 activity. Here we demonstrate for the ﬁrst time that as
with PDE3, PDE4 and PDE5, PDE8 can be phosphorylated and acti-
vated by PKA and this action serves to enhance enzyme activity at
times of elevated cAMP. Surprisingly, this modiﬁcation does not
occur in regions that are thought to be important for PDE8 regula-
tion, namely the REG or PAS domains [9–11] (see Fig. 1), however,
this represents the ﬁrst report of a post-translation modiﬁcation of
PDE8. In discovering this novel point of cAMP control, we have
developed a novel antibody that can detect the phosphorylation
of PDE8 in cells and we hope that use of this biological tool will
facilitate a better understanding of the mechanisms underpinning
PDE8 function.
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